Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5/26/2011 4:59:34 PM
More...
|
Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
9/29/2010 8:15:51 AM
More...
|
Tigris Pharmaceuticals Completes $6.5 Million Private Placement
9/29/2010 8:10:59 AM
More...
|
First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418
5/1/2009 12:03:24 PM
More...
|
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at American Association for Cancer Research Annual Meeting
4/30/2009 9:46:19 AM
More...
|
Tigris Pharmaceuticals Appoints Pedro Granadillo as Chairman of Board of Directors
4/16/2009 9:49:17 AM
More...
|
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals's GGTI-2418
3/4/2009 8:37:51 AM
More...
|
Tigris Pharmaceuticals Files IND Application for GGTI-2418
2/6/2009 8:35:35 AM
More...
|
Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
5/15/2008 8:08:53 AM
More...
|
Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
1/31/2008 9:55:27 AM
More...
|
|